Print This PostWhen a clinical study finally receives that long‑awaited approval and the research site transitions from planning into real‑world delivery, one of the most critical milestones is the Site Initiation Visit (SIV). This visit acts as the launch point for the entire study, ensuring the site is fully prepared for activation and marking the moment when the participant journey truly begins.
This blog explores the purpose of an SIV, what typically occurs during one, why it matters, and how it strengthens research integrity and safeguards participants. Understanding the SIV is essential for anyone involved in delivering clinical trials, from principal investigators to research nurses, coordinators, and sponsors.
Having attended many SIVs throughout my research career, I understand why they are sometimes viewed as just another meeting or a tick‑box step in the long study‑setup process. However, the SIV plays a crucial role: it ensures that each research site, every member of the study team, and all protocol‑driven activities are fully prepared to deliver the trial safely, consistently, and in complete alignment with Good Clinical Practice (GCP).
What Exactly Is a Site Initiation Visit?
A Site Initiation Visit (SIV), often referred to as a study start‑up visit, can only take place once the site has been formally selected and all essential regulatory and organisational agreements have been fully executed. The purpose of the SIV is to ensure that the site is fully prepared before any participants are approached, screened, or enrolled. Led by the study sponsor, a Clinical Research Associate (CRA), or a designated study monitor, the visit covers all critical components of the study, including a detailed review of the protocol and any required training for the research team.
What Happens During an SIV?
Although SIVs can vary depending on the sponsor, the complexity of the study, and the organisational structure of the site, they typically follow a common framework. Most include several core components that together create a thorough assessment and training session for the research team. The following paragraphs provide a brief description of the key elements covered at an SIV.
Protocol Training
At the heart of every SIV is the comprehensive review of the study protocol. The CRA guides the team through the key elements, including inclusion and exclusion criteria, visit schedules, assessments, endpoints, and safety monitoring requirements. The protocol provides the foundational framework for how the trial must be carried out, and the SIV ensures that every member of the team, from the Principal Investigator to administrative staff understands how it should be implemented. It is also an opportunity for staff to ask questions and raise practical issues.
Roles, Delegation, and Responsibilities
Clear responsibilities are key to successful study delivery. During the SIV, the delegation log is reviewed, and each task is assigned to appropriately qualified members of the research team. Clarification on delegated responsibilities such as who will obtain informed consent, enter data, complete case report forms and who will report adverse events will be clearly identified. By the end of the SIV, every team member should understand not only their own responsibilities but also the responsibilities of others, reducing confusion and promoting accountability.
Regulatory and Documentation Review
The CRA checks that all Ethics and R&D approvals are in place and that the Investigator Site File (ISF) contains all required essential documents. This includes approvals, CVs, training records, signed protocols, delegation logs, and other study‑critical documentation. Any gaps are addressed during the SIV to ensure that the site is fully compliant before recruitment begins.
Data Management and Recording
Accurate and high‑quality data collection is central to research validity. During the SIV, the CRA reviews how source data should be documented, how data should be entered into the study database, and what procedures should be followed if errors or deviations occur. The monitoring plan is also discussed so that the site understands how and when data will be reviewed throughout the trial.
Pharmacy and IMP Processes
In studies involving an investigational medicinal product (IMP), the SIV includes dedicated discussions with the pharmacy team. This covers storage conditions, temperature monitoring, drug accountability, dispensing procedures, and how unused medication should be returned or destroyed. Pharmacy staff play a critical role in ensuring drug safety and compliance, making this a key focus area.
As you will have read, a Site Initiation Visit is far more than a routine administrative step. It requires collaboration, communication and an understanding of what’s expected from the sponsor and the research site. The SIV equips the research team with a deeper understanding of the study protocol and introduces the strategies and tools needed for successful study delivery. By confirming that the team is fully prepared and trained, documentation is complete, and all procedures are clearly defined, the SIV lays the groundwork for reliable results. Ultimately, it creates the foundation for a compliant, safe, and high‑quality clinical trial before the first participant is ever approached.
Jacqueline Kerr
Author
Jacqueline Kerr is the Network Manager for the Neuroprogressive and Dementia Network in Scotland. With a background in research management and public engagement, she is dedicated to supporting clinical trials and improving access to research across the country. Jacqueline works closely with clinicians, researchers, and the public to raise awareness of dementia studies and encourage participation.
Dr Clíona Farrell
Dr Becky Carlyle
Dr Emma Law
Dr Yvonne Couch